“Imugene has recently proven the efficacy of a new porcine vaccine for PRRS……..Existing vaccines have efficacy and safety issues and Imugene’s trial results are very promising.”
“The market has responded firmly increasing the share price by almost 30%. There should be more good news released in the next few months relating to trials from it’s chicken productivity enhancement product if all goes as expected.”
Imugene soars on vaccine trial result.
Australian Biotechnology News by Graeme O'Neill
“Shares in Sydney animal-health biopharma Imugene Limited (ASX:IMU) soared yesterday on news that animal trials have confirmed the efficacy of the company's new vaccine for controlling one of the international pig industry's most costly diseases.
Imugene's ASX announcement yesterday said a preliminary estimate was that an effective PRSS vaccine could achieve international revenues of US$100 million (AUD$137 million) a year. Those revenues could double or triple if the vaccine were used in a global campaign to eradicate PRSS from the pig industry”. -------------------------------------------------------------------------------- March 2004 – Biotechs bounce back.
Shares Magazine – March 2004 issue - Mark Pachacz & David Blake ”The emergence of a novel and dangerous avian strain of the influenza virus has been cause for worldwide alarm.
In Australia, researchers working at the CSIRO have teamed up with Imugene and started work on developing a vaccine for Australian chickens in the event of the virus finding its way into the country. Imugene is developing several improved vaccines for the poultry and pork industries using its viral-delivery vector system”. -------------------------------------------------------------------------------- February 6th 2004 – Imugene, Working on the national interest.
Bioshares – Issue 57 - Mark Pachacz & David Blake
“Is it just getting on the bandwagon for a short term boost to its share price? In fact the CSIRO approached Imugene to co-develop this vaccine as a matter of national interest.” -------------------------------------------------------------------------------- February 4th 2004 - CSIRO, Imugene cooperate on bird flu vaccine project
By - Graeme O'Neill, Australian Biotechnology News
“CSIRO Livestock Industries and its animal health spin-off Imugene (ASX:IMU) have begun a joint research project to develop a vaccine to protect chickens against the deadly new strain of avian influenza devastating poultry farms in Asia.” Chris Prideaux (CSIRO) said there had been five outbreaks of avian influenza on Australian poultry farms since 1976, and in each, there was circumstantial or obvious evidence of contact with waterfowl. None of the outbreaks, which caused severe disease in chickens, involved the H5N1 serotype.” -------------------------------------------------------------------------------- October 6 2003 – Sydney Morning Herald – From AAP
Biotechs outpace the rest of sharemarket by eight-to-one
“Australia's biotechnology stocks have had a stellar rise since the start of 2003, growing at eight times the pace of the general market.”
“Intersuisse's head of research, Peter Russell, attributed the growth to an overall upswing in the market as well as solid underlying fundamentals among biotech companies.” -------------------------------------------------------------------------------- 26th September 2003 – Australian Biotechnology News – By Melissa Trudinger
Tech tweak boosts Imugene
"Our initial in vitro tests with the chicken productivity enhancer have shown that the modification to the vector has resulted in gamma interferon levels up to 50 times higher than the original product," said managing director Dr Warwick Lamb.
-------------------------------------------------------------------------------- 16th September 2003 – Australian Biotechnology News – By Melissa Trudinger
Imugene toasts future after formative year
veterinary biotechnology company Imugene (ASX:IMU) has come a long way in its first year as a biotechnology company, according to chairman Graham Dowland, who said it was a "tremendous formative year."
……the key defining moment for the company financially has been licence agreements for four of the company's products with two of the major multinational animal health groups, Merial and Intervet, providing revenues of $538,444.
IMU Price at posting:
0.0¢ Sentiment: None Disclosure: Held
(20min delay)